Welcome to our dedicated page for Sohm news (Ticker: SHMN), a resource for investors and traders seeking the latest updates and insights on Sohm stock.
Overview
SOHM Inc (SHMN) is a dynamic biopharmaceutical and biotechnology company that seamlessly integrates traditional pharmaceutical manufacturing with state‐of‐the‐art gene editing technologies. With core operations in manufacturing generic drugs, nutraceuticals, and cosmeceuticals, the company addresses a broad spectrum of therapeutic treatment categories while also innovating in precision medicine. At the forefront of its technology portfolio is the revolutionary ABBIE (A Binding Based Integrase Enzyme) system, which is designed for precise genome editing and has paved the way for advanced applications such as CAR-T cell therapy and targeted gene integrations. Keywords such as pharmaceutical, biotechnology, and gene editing emphasize its dual focus and technical expertise.
Business Model and Operations
SOHM Inc generates revenue primarily through the manufacturing and marketing of generic drugs and diversified cosmeceutical products aimed at dermatological and prescription skincare markets. The company leverages its manufacturing facilities to produce a range of high-quality, cost-efficient therapies while integrating innovative biotechnological solutions for gene therapies. Their recent strategic collaborations highlight an advanced approach to drug delivery and genome editing, enabling safer, non-viral methods for gene integration. The operational blueprint not only spans laboratory research and development but also includes commercialization of off-the-shelf genome editing kits, illustrating its robust and multifaceted business model.
Technological Prowess and Industry Positioning
Central to SOHM's competitive edge is their ABBIE gene editing technology, which is engineered to offer faster, more precise, and safer genomic modifications. This system is uniquely positioned to enhance genetic research and therapeutic development by reducing off-target effects and streamlining the integration of donor DNA. Their collaborations with leading institutions and biotechnology companies further cultivate an environment of continuous innovation, enabling breakthroughs that address longstanding challenges in genome editing and drug delivery systems. Furthermore, their interests in evolving areas like CAR-T cell therapies underscore their commitment to precision medicine and personalized treatment approaches.
Research, Innovation, and Strategic Collaborations
SOHM Inc places a strong emphasis on research and development. The company has built a robust patent portfolio around its innovative genomic technologies, reinforcing its market credibility and leadership in the field. Strategic partnerships with biotechnology firms and renowned academic institutions facilitate joint research projects, grant writing initiatives, and technology development programs. These collaborations not only validate the technical aspects of their proprietary methods but also position SOHM as a trusted innovator capable of addressing the complexities of modern biomedicine.
Market Significance and Competitive Landscape
Operating in a competitive landscape that includes established biotech and pharmaceutical firms, SOHM Inc distinguishes itself through its integrated approach to both generic drug production and advanced gene editing. This dual strategy allows them to tap into multiple revenue streams while maintaining flexibility in the face of evolving market demands. Their involvement in both traditional pharmaceutical markets and emerging gene therapy applications exemplifies a comprehensive business strategy designed to capture market share and respond efficiently to investor interest in technological advancements.
Commitment to Safety and Quality
In all of its operations, SOHM Inc maintains a strong commitment to quality, safety, and innovation. By utilizing natural and biocompatible delivery systems, and by focusing on research-driven product development, the company aims to ensure higher efficiency and reduced risk in genetic modifications. The emphasis on clear operational protocols and rigorous R&D processes further underscores the company’s dedication to advancing therapeutic science in a methodical and reliable manner.
Conclusion
SOHM Inc stands as a multifaceted entity in the pharmaceutical and biotechnology sectors. With a solid foundation in generic drug manufacturing and an aggressive push into advanced genome editing, the company presents a compelling case study in modern integrated biomedicine. Its strategic collaborations, deep R&D expertise, and strong commitment to developing safer, efficient therapeutic solutions securely position it as a noteworthy, innovative player in the rapidly evolving biotech landscape.
SOHM Inc (OTC PINK:SHMN) has announced significant developments in their ABBIE Technology, revealing a strategic pivot in their business model. The company is transitioning from selling ABBIE kits for independent use to establishing a licensing model, leveraging their global Intellectual Property portfolio.
The company's breakthrough findings indicate that ABBIE technology features unique traceability capabilities absent in competing technologies, potentially streamlining FDA approval processes and enhancing therapy safety. SOHM is currently in technical diligence discussions with both small innovators and major pharmaceutical companies, focusing on applications in CAR-T therapy, cancer drug development, and gene therapy.
The company plans to publish these findings in Q2 2025 and will organize platform seminars to showcase the technology's potential in revolutionizing cancer treatment.
SOHM Inc. (OTC PINK:SHMN) has appointed Dr. Wei Zhu as Senior Marketing and Sales Consultant for its biotech ABBIE division. Dr. Zhu brings over 20 years of experience in Molecular and Cellular Biology, Biochemistry, Immunology, Signal Transduction, Cancer Biology, and Developmental Biology. Her expertise includes advanced Bioinformatics, Sequence-based Genomics Research, Histology, and animal model work. The appointment is effective immediately, and she will contribute to the company's marketing and sales efforts in pharmaceutical, cosmeceutical, and nutraceutical products.
SOHM Inc (OTC PINK:SHMN) has received a patent allowance from Japan's Patent Office for its ABBIE Genome Editing technology. The patent (No. 2023-121860) protects SOHM's innovative SAGE (SOHM-ABBIE Genome Editing) products and services, which enable precise DNA alterations without causing double-stranded breaks. This technology advancement positions SOHM competitively in the global Cell Therapy market, valued at $4.5 Billion in 2023 and projected to reach $97 Billion by 2033. The company plans to expand its presence in Japan, Korea, China, EU, and other global markets through product sales, services, and strategic partnerships.
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has appointed Dr. David Zarling as its Senior Product Development Advisor. Dr. Zarling brings extensive experience in biotechnology, pharmaceuticals, and nutraceuticals, having served in advisory roles at SRI International-BioSciences Division, Pangene , and Colby Pharmaceutical Company. His expertise spans product development, strategic partnering, and innovation in biologic and pharma drug solutions.
Dr. Zarling's background includes work in oncology, immunology, inflammation, infectious and neurodegenerative diseases. His appointment is expected to contribute to SOHM's product development, marketing, and sales efforts, including the company's ABBIE technology products. CEO Baron Night expressed confidence that this addition will help achieve higher revenue growth in 2024 compared to previous years.
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has filed a new provisional patent application with the USPTO. The application, titled 'DONOR NUCLEIC ACIDS FOR RNA GUIDED INTEGRASES AND MULTIPLEX GUIDE RNA SYSTEM FOR TARGETING', describes specific combinations of guide RNAs used with the ABBIE system to increase targeting and efficiency.
This development comes ten months after SOHM's announcement of their 'SMART' gene editing provisional application. The company aims to expand its patent portfolio in the cell engineering space, with the goal of becoming a significant player and leader in gene editing technology and products.
Dr. David Aguilar, COO of SOHM, expressed satisfaction with the progress in developing the ABBIE system and its potential, stating that these technical advances provide the competitive edge needed in this highly contested field.
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced receiving pre-launch orders for their ABBIE Technology kits. This marks a significant milestone as the company transitions from R&D to commercialization of GLP ABBIE Technology Kits. The CRISPR/Cas9 kits market is projected to reach $17.4 billion by 2032.
SOHM's ABBIE technology offers faster and more efficient integration of genetic sequences into cell DNA compared to traditional methods, reducing time and costs. The company's data shows that ABBIE expressing mRNA with guide RNAs integrates donor DNA more efficiently than without guide RNAs.
Management is confident that these pre-launch orders will open new opportunities for their technology. They plan to share updates on collaborations, including one with Stanford Medicine. SOHM aims for higher revenue growth in 2024, partly driven by the new ABBIE kits.
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced the appointment of Dr. Tetsuya Kawamura, Ph.D., as a Senior Cell Engineer and Biochemist. Dr. Kawamura brings extensive experience in biochemistry, molecular biology, and cellular biology. He has a proven track record in developing new methods for cell model creation, protein expression, and DNA/RNA production. Notably, Dr. Kawamura has authored patents in gene editing technology, including SOHM's ABBIE technology.
Dr. Kawamura's appointment is expected to enhance SOHM's scientific capabilities and support the advancement and commercialization of their ABBIE gene editing technology. The company anticipates that his expertise will aid in the timely release of ABBIE kits, as previously announced for the current quarter.
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has signed a manufacturing and supply agreement for skincare topical products with new export customers. The company has dispatched its first initial purchase order of 7,500 units to a new Far East customer, which is expected to generate over a quarter million in revenue during 2024. SOHM's Carlsbad facility will handle production for ongoing regular orders.
The agreement covers human prescription topical treatments for skin care, acne, exfoliation, and anti-aging. SOHM plans to expand its business through private label agreements and CDMO activities with other domestic and export customers. The company aims to capture a substantial market share in 2024, building on its success with other product lines, including the recently introduced ABBIE kits.
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced a new collaboration with Stanford University. This partnership aims to advance cell engineering and gene editing through SOHM's ABBIE Technology. The collaboration will involve joint research projects, knowledge-sharing initiatives, and technology development programs.
Dr. David Aguilar, COO of SOHM, expressed excitement about the partnership, stating that it will amplify their impact and foster innovation. Specific projects and initiatives under this collaboration are expected to be unveiled in the coming months. This strategic alliance combines SOHM's innovative prowess with Stanford's expertise to tackle challenges in gene editing development.
SOHM has announced promising preliminary data from their ABBIE genome editing technology, showcasing successful engineering of a CAR-T cell from a healthy donor that killed lung cancer cells in experimental models. This breakthrough, presented at the 2024 AACR conference, highlights ABBIE's novel approach, utilizing mRNA or purified protein delivery instead of traditional virus-based systems. This could offer a more efficient and less toxic method for developing cancer immunotherapies. The market for such therapies is projected to grow significantly, with CAR T-cell therapy costs ranging from $373,000 to $475,000 per patient.
FAQ
What is the current stock price of Sohm (SHMN)?
What is the market cap of Sohm (SHMN)?
What is the primary focus of SOHM Inc?
How does SOHM Inc generate its revenue?
What is ABBIE technology?
How do strategic partnerships enhance SOHM Inc's capabilities?
What differentiates SOHM Inc in the competitive biotech landscape?
What applications does ABBIE technology have?
How does SOHM Inc maintain quality and safety in its operations?
What market segments does SOHM Inc serve?
